Table 1 Characteristics of HIV-HCV coinfected patie nts treated with antiretroviral therapy at the time of liver biopsy (parameters collected the day of the liver biopsy or during the week before)

Median age at biopsy (IQR), years

41 (36-45)

Male, n (%)

154 (84)

Ethnicity, n (%)

Caucasian

163 (89)

Black

21 (11)

Intravenous drug use, n (%)

127 (61)

Alcohol use, n (%)*

67 (36)

Median duration of HIV diagnosis (IQR, years

11 (7-14)

Median CD4 cell counts/mm³ (IQR)

321 (227-461)

Undetectable HIV RNA⁺, n (%)

119 (67)

HCV genotype⁺⁺, n (%)

1

98 (55)

2

10 (6)

3

47 (26)

4

24 (13)

Median HCV RNA (IQR), log₁₀ KIU/ml⁺⁺⁺

6.18 (5.76-6.60)

Median laboratory variables (IQR), U/l

ALT

83 (47-128)

AST

65 (43-97)

Alkaline phosphatase

89 (71-113)

GGT

80 (42-160)

Median glycemia (IQR), mmol/l

4.8 (4.3-5.3)

Glycemia 5.6mmol/l⁺, n (%)

33 (19)

Glycemia7.0mmol/l⁺, n (%)

7 (4)

Median total cholesterol (IQR), mmol/l

4.20 (3.54-5.10)

Median triglyceridemia (IQR), mmol/l

1.49 (0.99-2.10)

Triglyceridemia 1.7mmol/l⁺, n (%)

60 (36)

Median duration of antiretroviral therapy (IQR), months

58 (28-94)

Median cumulative exposure to antiretrovirals (IQR), months

NRTI

56 (28-90)

NNRTI

16 (9-31)

PI

23 (12-40)

Combination of ART at liver biopsy, n (%)

2 NRTI+1 PI

93 (51)

2 NRTI+1 NNRTI

36 (20)

1 or 2 NRTI

31 (16)

3 NRTI

17 (9)

Other regimens

7 (4)